These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28195508)

  • 1. Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.
    Giorgi Rossi P; Carretta E; Mangone L; Baracco S; Serraino D; Zorzi M;
    J Med Screen; 2018 Mar; 25(1):32-39. PubMed ID: 28195508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.
    Zorzi M; Hassan C; Senore C; Capodaglio G; Turrin A; Narne E; Mussato A; Rizzato S; Chinellato E; Zamberlan S; Repici A; Rugge M
    J Med Screen; 2021 Jun; 28(2):131-139. PubMed ID: 32393153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proportional incidence of interval colorectal cancer in a large population-based faecal immunochemical test screening programme.
    Mancini S; Bucchi L; Giuliani O; Ravaioli A; Vattiato R; Baldacchini F; Ferretti S; Sassoli de Bianchi P; Mezzetti F; Triossi O; Serafini M; Ricci E; Palazzi M; Imolesi C; Giovanardi M; Canuti D; Voci C; Altini M; Falcini F
    Dig Liver Dis; 2020 Apr; 52(4):452-456. PubMed ID: 32165075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy.
    Zorzi M; Fedato C; Grazzini G; Stocco FC; Banovich F; Bortoli A; Cazzola L; Montaguti A; Moretto T; Zappa M; Vettorazzi M
    Gut; 2011 Jul; 60(7):944-9. PubMed ID: 21193461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence.
    Ventura L; Mantellini P; Grazzini G; Castiglione G; Buzzoni C; Rubeca T; Sacchettini C; Paci E; Zappa M
    Dig Liver Dis; 2014 Jan; 46(1):82-6. PubMed ID: 24011791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
    Castiglione G; Visioli CB; Ciatto S; Grazzini G; Bonanomi AG; Rubeca T; Mantellini P; Zappa M
    Br J Cancer; 2007 Jun; 96(11):1750-4. PubMed ID: 17453007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
    Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
    Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study.
    Vicentini M; Zorzi M; Bovo E; Mancuso P; Zappa M; Manneschi G; Mangone L; Giorgi Rossi P;
    Int J Cancer; 2019 Jul; 145(1):110-121. PubMed ID: 30585621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.
    Zorzi M; Fedeli U; Schievano E; Bovo E; Guzzinati S; Baracco S; Fedato C; Saugo M; Dei Tos AP
    Gut; 2015 May; 64(5):784-90. PubMed ID: 25179811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
    Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
    Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for colorectal cancer in Italy: 2011-2012 survey.
    Zorzi M; Mangone L; Sassatelli R; Baracco S; Budroni M; Castaing M; Cirilli C; Cusimano R; Fusco M; Giacomin A; Giorgi Rossi P; Naldoni C; Pannozzo F; Piffer S; Puppo A; Tisano F; Zappa M;
    Epidemiol Prev; 2015; 39(3 Suppl 1):115-25. PubMed ID: 26405783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
    Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
    Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer in a second round after a negative faecal immunochemical test.
    Bujanda L; Sarasqueta C; Castells A; Pellisé M; Cubiella J; Gil I; Cosme A; Arana-Arri E; Mar I; Idigoras I; Portillo I;
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):813-8. PubMed ID: 25856688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
    Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
    Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screenees in a Colorectal Cancer Screening Program.
    de Klaver W; van der Vlugt M; Spaander MCW; Bossuyt PM; Dekker E
    Gastroenterology; 2024 Sep; 167(4):788-797.e2. PubMed ID: 38697486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric cancer after positive screening faecal occult blood testing and negative assessment.
    Zappa M; Visioli CB; Ciatto S; Grazzini G; Rubeca T; Bonanomi AG; Confortini M; Paci E; Castiglione G
    Dig Liver Dis; 2007 Apr; 39(4):321-6. PubMed ID: 17314076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
    Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
    Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.